+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biotechnology Industry Forecasts - China Focus

  • PDF Icon

    Report

  • 102 Pages
  • July 2024
  • Region: China
  • AMID Co
  • ID: 3397745
This study focuses on China’s Biotechnology industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market.

Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products.

This new study focuses on industry trends and forecasts with historical data (2013, 2018 and 2023) and long-term forecasts through 2028 and 2033 are presented.

The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and in-house databases.

Table of Contents

INTRODUCTION
  • Report Scope and Methodology
  • Executive Summary
BUSINESS ENVIRONMENT
  • Economic Outlook
  • Key Economic Indicators
  • Industrial Output
  • Population and Labor
  • Foreign Investment
  • Foreign Trade
  • Financial and Tax Regulations
  • Banking System and Regulations
  • Foreign Exchange
  • Taxes, Tariff and Custom Duties
BIOTECHNOLOGY PRODUCTS SUPPLY AND DEMAND
  • Overview
  • Biotechnology in Agriculture
  • Transgenic Agricultural Products Output
  • Transgenic Crops
  • Transgenic Fruits and Vegetables
  • Transgenic Seeds and Plants
  • Transgenic Oil Crops
  • Other Transgenic Products in Agriculture
  • Biopesticides
  • Animal Growth Hormones
  • Biotechnology Pharmaceuticals
  • Biotechnology Vaccines
  • CSF
  • Recombinant Human Erythropoietin (r-EPO)
  • Recombinant Human Insulin
  • Recombinant Human Growth Hormones
  • Recombinant Interferon
  • Other Biotechnology Pharmaceuticals
  • Demand of Biotechnology Pharmaceutical by Region
  • Biotechnology Pharmaceutical Imports and Exports
  • Pricing Trend
LIST OF TABLES
INTRODUCTION
  • Economic Outlook Summary
BUSINESS ENVIRONMENT
  • Key Economic Indicators
  • Industrial Output
  • Population and Labor Force Trends
  • Foreign Investment and Loans
  • Foreign Trade
BIOTECHNOLOGY PRODUCTS SUPPLY AND DEMAND
  • Biotechnology Products Production and Demand
  • Transgenic Crops Production and Demand
  • Transgenic Fruits and Vegetables Production and Demand
  • Transgenic Seeds and Plants Production and Demand
  • Transgenic Oil Crops Production and Demand
  • Other Transgenic Products in Agriculture Production and Demand
  • Biopesticides Production and Demand
  • Animal Growth Hormones Production and Demand
  • Biotechnology Vaccines Production and Demand
  • CSF Production and Demand
  • r-EPO Production and Demand
  • Recombinant Human Insulin Production and Demand
  • Recombinant Human Growth Hormones Production and Demand
  • Recombinant Interferon Production and Demand
  • Other Biotechnology Pharmaceuticals Production and Demand
  • Demand of Biotechnology Pharmaceuticals by Region
  • Biotechnology Pharmaceuticals Imports and Exports
LIST OF CHARTS
INTRODUCTION
  • China’s Biotechnology Pharmaceuticals Output and Demand
BUSINESS ENVIRONMENT
  • China’s GDP and Growth Rate
  • Industrial Output by Ownership
  • China’s Imports and Exports
BIOTECHNOLOGY PRODUCTS SUPPLY AND DEMAND
  • Biotechnology in Agriculture Production and Demand
  • Biotechnology Pharmaceuticals Production and Demand
  • Biotechnology Pharmaceuticals Exports and Imports

Executive Summary



Focus on China’s Healthcare for 1.3 Billion People

In the two past decades, the healthcare industry has been growing at a fast pace. It is a tremendous challenge to provide healthcare for 1.3 billion people. The dramatic expansions of the healthcare system, drug manufacturing, and health insurance have transformed China’s society and economy. Life expectancy reached 76.8 for women and 72.5 for men now comparing to 69.9 for women and 66.9 for men in 1990. Demographic transition from high mortality to low mortality has helped increase life expectancy. Primary diseases have also shifted from infectious to chronic. Cancer, heart diseases and cerebrovascular diseases are now top killers. Spending on healthcare counts for over 5% of GDP now and continue to increase in the next decade.

Healthcare reform has been one of the key topics on the government agenda in China. Due to the rise in the cost of healthcare, more than 10% of the income is spent on healthcare, which is greater than that spent on education and transportation. The rise in the cost in healthcare would definitely have an outcome of the high cost of the drugs.

There are approximately 4,500 pharmaceutical companies in China, the majority of which are small players with limited local market reach. Rapid consolidation between medium and large players in the sector is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to better control the pricing of drugs.

China is one of the world’s major producers of pharmaceuticals. Far outpacing other economies in the world, China is the world’s fastest growing pharmaceutical market. Although China has enjoyed the benefits of an expanding market for pharmaceutical production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers in the pharmaceutical industry lack the autonomic intellectual property and financial resources to develop their own brand name products. Most manufacturers rely on the repetitive production of Chinese medicine, low value-added bulk pharmaceuticals or generic drugs.

Biotechnology is a rapidly growing sector in China. Both production and demand have witnessed significant surges in recent years. China will continue to remain a large importer for biotechnology pharmaceuticals to meet the growing domestic demand. Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.

The health care insurance industry of China includes two main parts such as the social healthcare insurance controlled by the government and commercial healthcare insurance provided by private companies. At present, the social healthcare insurance is under reforms to control the increasing healthcare costs. The development of commercial healthcare insurance in China is not inadequate. But the commercial healthcare insurance market has a great growth potential. Today, China has the largest healthcare market in the world. The Chinese healthcare industry is one of the fastest-growing sectors in China, growing at double digit rate each year. Tremendous fast-growing markets for imports and business opportunities for companies around the world.